On March 30, 2017 Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, reported its broad presence at the upcoming 108th Annual Meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) being held April 1 to 5, 2017, in Washington, D.C., including 14 presentations on antibody-drug conjugate (ADC) and immuno-oncology technology advances and development programs (Press release, Seattle Genetics, MAR 30, 2017, View Source;p=RssLanding&cat=news&id=2257546 [SID1234518388]). Data in multiple presentations demonstrate potential improvements in linker technologies for multiple payloads which may enable development of novel ADCs, including the planned clinical program SGN-CD48A for multiple myeloma. The company’s SGN-2FF program was selected for an oral presentation in the New Drugs on the Horizon symposium focusing on the preclinical rationale and phase 1 trial design for this small molecule immuno-oncology agent. Seattle Genetics’ scientific leadership will also be featured in an Educational Session and a Forum focused on advances in ADC research and the value of ADCs over other drug conjugate therapeutics in the cancer treatment landscape.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Over nearly 20 years, Seattle Genetics has continued its tradition of innovation to produce industry-leading ADC and empowered-antibody technologies designed to improve outcomes for patients with cancer," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development, at Seattle Genetics. "In 14 presentations, including four orals, our new data at the AACR (Free AACR Whitepaper) Annual Meeting will highlight key improvements to linker technologies for cancer cell-killing payloads, including novel auristatins and tubulysins, preclinical combination regimens with checkpoint inhibitors, and progress with our immuno-oncology therapeutic candidates."
ADCs are targeted cancer treatments that harness the specificity of antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS, Seattle Genetics’ first commercially available product, vadastuximab talirine, a phase 3 candidate in acute myeloid leukemia (AML), and enfortumab vedotin, an advancing clinical-stage bladder cancer candidate, are three of more than 20 ADCs in clinical development using the company’s proprietary technology.
Multiple oral and poster presentations are being featured at AACR (Free AACR Whitepaper) that highlight Seattle Genetics’ ADC and immuno-oncology advances. Abstracts can be found at www.aacr.org and include the following:
Saturday, April 1, 2017
Expanding the payload scope and drug load of ADCs through drug-linker design (Session #ED03, oral presentation at 2:00 p.m. ET)
Sunday, April 2, 2017
Antibody-drug conjugates containing glucuronide-tubulysin payloads display activity in MDR+ and heterogeneous tumor models (Abstract #56, poster presentation)
Reducing toxicity of antibody-drug conjugates through modulation of pharmacokinetics (Abstract #60, poster presentation)
Elucidating the roles of antibody pharmacokinetics and maleimide stability in the toxicology of antibody-drug conjugates (Abstract #70, poster presentation)
Development of homogeneous dual-drug ADCs: Application to the co-delivery of auristatin payloads with complementary antitumor activities (Abstract #982, oral presentation at 4:05 p.m. ET)
SGN-2FF: A Novel Small Molecule Inhibitor of Fucosylation with Preclinical Antitumor Activity through Multiple Immune Mechanisms (Abstract #DDT02-02, oral presentation at 3:24 p.m. ET)
Monday, April 3, 2017
Cysteine Mutant Location Affects Chemotype Lability in Site-Specific Antibody Drug Conjugates (Abstract #LB-066, poster presentation)
Targeted Delivery Using Antibody Drug Conjugates (Session #FO01, oral presentation at 5:00 p.m. ET)
Tuesday, April 4, 2017
Therapeutic activity of effector function-enhanced, non-fucosylated anti-CD40 antibodies in preclinical immune-competent rodent tumor models (Abstract #3647, poster presentation)
Superior T cell activity of a membrane-proximal binding antibody when targeting Glypican-3 with an Antibody-Coupled T cell Receptor (ACTR) armed T cell (Abstract #3762, poster presentation; collaboration with Unum Therapeutics)
Effect of PEG Chain length on Antibody-Drug Conjugate Tumor and Tissue Distribution in Tumor Bearing Xenograft Mice (Abstract #4075, poster presentation)
Efficient targeting of BCMA-positive multiple myeloma cells by Antibody-Coupled T cell Receptor (ACTR) engineered autologous T cells in combination with an anti-BCMA antibody (Abstract #4605, poster presentation; collaboration with Unum Therapeutics)
Assessment of Myeloblast CD33 Receptor Occupancy (RO) by Vadastuximab Talirine in Patients with Acute Myeloid Leukemia (AML) Receiving Monotherapy Treatment (Abstract #CT120, poster presentation)
Wednesday, April 5, 2015
Brentuximab vedotin-driven immunogenic cell death enhances antitumor immune responses, and is potentiated by PD1 inhibition in vivo (Abstract #5588, poster presentation)